{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T14:22:29Z","timestamp":1783088549813,"version":"3.54.6"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,7,17]],"date-time":"2023-07-17T00:00:00Z","timestamp":1689552000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,7,17]],"date-time":"2023-07-17T00:00:00Z","timestamp":1689552000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Multiple myeloma bone disease is characterized by the development of osteolytic bone lesions. Recent work identified matrix metalloproteinase 13 as a myeloma-derived fusogen that induces osteoclast activation independent of its proteolytic activity. We now identify programmed death-1 homolog, PD-1H, as the bona fide MMP-13 receptor on osteoclasts. Silencing PD-1H or using<jats:italic>Pd-1h<\/jats:italic><jats:sup><jats:italic>-\/<\/jats:italic>-<\/jats:sup>bone marrow cells abrogates the MMP-13-enhanced osteoclast fusion and bone-resorptive activity. Further, PD-1H interacts with the actin cytoskeleton and plays a necessary role in supporting c-Src activation and sealing zone formation. The critical role of PD-1H in myeloma lytic bone lesions was confirmed using a<jats:italic>Pd-1h<\/jats:italic><jats:sup><jats:italic>-\/-<\/jats:italic><\/jats:sup>myeloma bone disease mouse model wherein myeloma cells injected into<jats:italic>Pd-1h<\/jats:italic><jats:sup><jats:italic>-\/-<\/jats:italic><\/jats:sup><jats:italic>Rag2<\/jats:italic><jats:sup><jats:italic>-\/-<\/jats:italic><\/jats:sup>results in attenuated bone destruction. Our findings identify a role of PD-1H in bone biology independent of its known immunoregulatory functions and suggest that targeting the MMP-13\/PD-1H axis may represent a potential approach for the treatment of myeloma associated osteolysis.<\/jats:p>","DOI":"10.1038\/s41467-023-39769-8","type":"journal-article","created":{"date-parts":[[2023,7,17]],"date-time":"2023-07-17T17:02:24Z","timestamp":1689613344000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["The checkpoint inhibitor PD-1H\/VISTA controls osteoclast-mediated multiple myeloma bone disease"],"prefix":"10.1038","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3894-722X","authenticated-orcid":false,"given":"Jing","family":"Fu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shirong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huihui","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel M.","family":"Pagnotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lewis M.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1864-6075","authenticated-orcid":false,"given":"Stephen J.","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus Y.","family":"Mapara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1708-7344","authenticated-orcid":false,"given":"Suzanne","family":"Lentzsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,17]]},"reference":[{"key":"39769_CR1","doi-asserted-by":"publisher","unstructured":"Marino, S., Petrusca, D. N. & Roodman, G. D. Therapeutic targets in myeloma bone disease. Br. J. Pharmacol. https:\/\/doi.org\/10.1111\/bph.14889 (2019).","DOI":"10.1111\/bph.14889"},{"key":"39769_CR2","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1002\/jcb.22403","volume":"109","author":"GD Roodman","year":"2010","unstructured":"Roodman, G. D. Pathogenesis of myeloma bone disease. J. Cell. Biochem. 109, 283\u2013291 (2010).","journal-title":"J. Cell. Biochem."},{"key":"39769_CR3","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1172\/JCI80276","volume":"126","author":"J Fu","year":"2016","unstructured":"Fu, J. et al. Multiple myeloma-derived MMP-13 mediates osteoclast fusogenesis and osteolytic disease. J. Clin. Invest. 126, 1759\u20131772 (2016).","journal-title":"J. Clin. Invest."},{"key":"39769_CR4","doi-asserted-by":"crossref","unstructured":"Kennedy, A. M. et al. MMP13 mutation causes spondyloepimetaphyseal dysplasia, Missouri type (SEMD(MO). J. Clin. Invest. 115, 2832\u20132842 (2005).","DOI":"10.1172\/JCI22900"},{"key":"39769_CR5","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1158\/0008-5472.CAN-13-1504","volume":"74","author":"JL Lines","year":"2014","unstructured":"Lines, J. L. et al. VISTA is an immune checkpoint molecule for human T cells. Cancer Res. 74, 1924\u20131932 (2014).","journal-title":"Cancer Res."},{"key":"39769_CR6","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1084\/jem.20100619","volume":"208","author":"L Wang","year":"2011","unstructured":"Wang, L. et al. VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses. J. Exp. Med. 208, 577\u2013592 (2011).","journal-title":"J. Exp. Med."},{"key":"39769_CR7","doi-asserted-by":"publisher","unstructured":"Li, S. et al. Targeting GCK pathway: a novel and selective therapeutic strategy against RAS mutated multiple myeloma. Blood https:\/\/doi.org\/10.1182\/blood.2020006334 (2020).","DOI":"10.1182\/blood.2020006334"},{"key":"39769_CR8","doi-asserted-by":"publisher","unstructured":"Blangy, A. et al. The osteoclast cytoskeleton\u2014current understanding and therapeutic perspectives for osteoporosis. J. Cell. Sci. 133, https:\/\/doi.org\/10.1242\/jcs.244798 (2020).","DOI":"10.1242\/jcs.244798"},{"key":"39769_CR9","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.ejcb.2005.09.008","volume":"85","author":"P Jurdic","year":"2006","unstructured":"Jurdic, P., Saltel, F., Chabadel, A. & Destaing, O. Podosome and sealing zone: specificity of the osteoclast model. Eur. J. Cell. Biol. 85, 195\u2013202 (2006).","journal-title":"Eur. J. Cell. Biol."},{"key":"39769_CR10","doi-asserted-by":"publisher","first-page":"191","DOI":"10.4161\/cam.27840","volume":"8","author":"D Georgess","year":"2014","unstructured":"Georgess, D., Machuca-Gayet, I., Blangy, A. & Jurdic, P. Podosome organization drives osteoclast-mediated bone resorption. Cell Adh. Migr. 8, 191\u2013204 (2014).","journal-title":"Cell Adh. Migr."},{"key":"39769_CR11","doi-asserted-by":"publisher","first-page":"2882","DOI":"10.1091\/mbc.e06-03-0187","volume":"17","author":"S Tehrani","year":"2006","unstructured":"Tehrani, S., Faccio, R., Chandrasekar, I., Ross, F. P. & Cooper, J. A. Cortactin has an essential and specific role in osteoclast actin assembly. Mol. Biol. Cell 17, 2882\u20132895 (2006).","journal-title":"Mol. Biol. Cell"},{"key":"39769_CR12","doi-asserted-by":"publisher","first-page":"13554","DOI":"10.1074\/jbc.M114.550731","volume":"289","author":"T Fukunaga","year":"2014","unstructured":"Fukunaga, T., Zou, W., Warren, J. T. & Teitelbaum, S. L. Vinculin regulates osteoclast function. J. Biol. Chem. 289, 13554\u201313564 (2014).","journal-title":"J. Biol. Chem."},{"key":"39769_CR13","doi-asserted-by":"publisher","first-page":"5169","DOI":"10.1158\/0008-5472.CAN-12-4501","volume":"73","author":"JR Stehn","year":"2013","unstructured":"Stehn, J. R. et al. A novel class of anticancer compounds targets the actin cytoskeleton in tumor cells. Cancer Res. 73, 5169\u20135182 (2013).","journal-title":"Cancer Res."},{"key":"39769_CR14","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1242\/jcs.090886","volume":"125","author":"J Takito","year":"2012","unstructured":"Takito, J. et al. The transient appearance of zipper-like actin superstructures during the fusion of osteoclasts. J. Cell. Sci. 125, 662\u2013672 (2012).","journal-title":"J. Cell. Sci"},{"key":"39769_CR15","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1172\/JCI74589","volume":"124","author":"DB Flies","year":"2014","unstructured":"Flies, D. B. et al. Coinhibitory receptor PD-1H preferentially suppresses CD4(+) T cell-mediated immunity. J. Clin. Invest. 124, 1966\u20131975 (2014).","journal-title":"J. Clin. Invest"},{"key":"39769_CR16","doi-asserted-by":"crossref","unstructured":"Slater, B. T., Han, X., Chen, L. & Xiong, Y. Structural insight into T cell coinhibition by PD-1H (VISTA). Proc. Natl Acad. Sci. USA 117, 1648\u20131657 (2020).","DOI":"10.1073\/pnas.1908711117"},{"key":"39769_CR17","doi-asserted-by":"publisher","first-page":"2954","DOI":"10.1128\/MCB.05611-11","volume":"32","author":"Y Kuroda","year":"2012","unstructured":"Kuroda, Y. et al. Cot kinase promotes Ca2+ oscillation\/calcineurin-independent osteoclastogenesis by stabilizing NFATc1 protein. Mol. Cell. Biol. 32, 2954\u20132963 (2012).","journal-title":"Mol. Cell. Biol."},{"key":"39769_CR18","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.ejcb.2010.07.006","volume":"90","author":"SE Winograd-Katz","year":"2011","unstructured":"Winograd-Katz, S. E., Brunner, M. C., Mirlas, N. & Geiger, B. Analysis of the signaling pathways regulating Src-dependent remodeling of the actin cytoskeleton. Eur. J. Cell. Biol. 90, 143\u2013156 (2011).","journal-title":"Eur. J. Cell. Biol."},{"key":"39769_CR19","doi-asserted-by":"crossref","first-page":"17124","DOI":"10.1074\/jbc.271.29.17124","volume":"271","author":"V Knauper","year":"1996","unstructured":"Knauper, V. et al. Cellular mechanisms for human procollagenase-3 (MMP-13) activation. Evidence that MT1-MMP (MMP-14) and gelatinase a (MMP-2) are able to generate active enzyme. J. Biol. Chem. 271, 17124\u201317131 (1996).","journal-title":"J. Biol. Chem."},{"key":"39769_CR20","doi-asserted-by":"publisher","unstructured":"ElTanbouly, M. A. et al. VISTA is a checkpoint regulator for naive T cell quiescence and peripheral tolerance. Science 367, https:\/\/doi.org\/10.1126\/science.aay0524 (2020).","DOI":"10.1126\/science.aay0524"},{"key":"39769_CR21","doi-asserted-by":"publisher","first-page":"2368","DOI":"10.1111\/j.1349-7006.2010.01675.x","volume":"101","author":"MA Sakr","year":"2010","unstructured":"Sakr, M. A. et al. GI24 enhances tumor invasiveness by regulating cell surface membrane-type 1 matrix metalloproteinase. Cancer Sci. 101, 2368\u20132374 (2010).","journal-title":"Cancer Sci."},{"key":"39769_CR22","doi-asserted-by":"publisher","first-page":"1261669","DOI":"10.1126\/science.1261669","volume":"349","author":"KW Yoon","year":"2015","unstructured":"Yoon, K. W. et al. Control of signaling-mediated clearance of apoptotic cells by the tumor suppressor p53. Science 349, 1261669 (2015).","journal-title":"Science"},{"key":"39769_CR23","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1038\/s41586-019-1674-5","volume":"574","author":"RJ Johnston","year":"2019","unstructured":"Johnston, R. J. et al. VISTA is an acidic pH-selective ligand for PSGL-1. Nature 574, 565\u2013570 (2019).","journal-title":"Nature"},{"key":"39769_CR24","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1111\/imm.13001","volume":"156","author":"J Wang","year":"2019","unstructured":"Wang, J. et al. VSIG-3 as a ligand of VISTA inhibits human T-cell function. Immunology 156, 74\u201385 (2019).","journal-title":"Immunology"},{"key":"39769_CR25","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41413-019-0080-9","volume":"8","author":"H Kim","year":"2020","unstructured":"Kim, H. et al. IgSF11 regulates osteoclast differentiation through association with the scaffold protein PSD-95. Bone Res. 8, 5 (2020).","journal-title":"Bone Res."},{"key":"39769_CR26","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1016\/j.celrep.2019.07.073","volume":"28","author":"N Mehta","year":"2019","unstructured":"Mehta, N. et al. Structure and functional binding epitope of V-domain Ig suppressor of T cell activation. Cell Rep. 28, 2509\u20132516.e2505 (2019).","journal-title":"Cell Rep."},{"key":"39769_CR27","doi-asserted-by":"publisher","unstructured":"Takito, J., Inoue, S. & Nakamura, M. The sealing zone in osteoclasts: a self-organized structure on the bone. Int. J. Mol. Sci. 19, https:\/\/doi.org\/10.3390\/ijms19040984 (2018).","DOI":"10.3390\/ijms19040984"},{"key":"39769_CR28","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1002\/jcp.24723","volume":"230","author":"J Takito","year":"2015","unstructured":"Takito, J. et al. Regulation of osteoclast multinucleation by the actin cytoskeleton signaling network. J. Cell. Physiol. 230, 395\u2013405 (2015).","journal-title":"J. Cell. Physiol."},{"key":"39769_CR29","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1359\/jbmr.071013","volume":"23","author":"Y Wang","year":"2008","unstructured":"Wang, Y. et al. Identifying the relative contributions of Rac1 and Rac2 to osteoclastogenesis. J Bone Miner. Res. 23, 260\u2013270 (2008).","journal-title":"J Bone Miner. Res."},{"key":"39769_CR30","doi-asserted-by":"publisher","first-page":"2641","DOI":"10.3389\/fimmu.2019.02641","volume":"10","author":"TWK Broughton","year":"2019","unstructured":"Broughton, T. W. K. et al. Defining the Signature of VISTA on Myeloid Cell Chemokine Responsiveness. Front. Immunol. 10, 2641 (2019).","journal-title":"Front. Immunol."},{"key":"39769_CR31","doi-asserted-by":"publisher","first-page":"2320","DOI":"10.1182\/blood-2019-131310","volume":"134","author":"P Shah","year":"2019","unstructured":"Shah, P. et al. VISTA is a novel regulator of macrophage biology. Blood 134, 2320 (2019).","journal-title":"Blood"},{"key":"39769_CR32","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1182\/blood-2016-03-707547","volume":"128","author":"G An","year":"2016","unstructured":"An, G. et al. Osteoclasts promote immune suppressive microenvironment in multiple myeloma: therapeutic implication. Blood 128, 1590\u20131603 (2016).","journal-title":"Blood"},{"key":"39769_CR33","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1002\/jbmr.2868","volume":"31","author":"L Ibanez","year":"2016","unstructured":"Ibanez, L. et al. Inflammatory osteoclasts prime TNFalpha-producing CD4(+) T CElls and Express CX3 CR1. J. Bone Miner. Res. 31, 1899\u20131908 (2016).","journal-title":"J. Bone Miner. Res."},{"key":"39769_CR34","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1182\/blood-2009-11-255026","volume":"116","author":"H Li","year":"2010","unstructured":"Li, H. et al. Cross talk between the bone and immune systems: osteoclasts function as antigen-presenting cells and activate CD4+ and CD8+ T cells. Blood 116, 210\u2013217 (2010).","journal-title":"Blood"},{"key":"39769_CR35","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.3389\/fimmu.2019.01408","volume":"10","author":"MB Madel","year":"2019","unstructured":"Madel, M. B. et al. Immune function and diversity of osteoclasts in normal and pathological conditions. Front. Immunol. 10, 1408 (2019).","journal-title":"Front. Immunol."},{"key":"39769_CR36","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.3389\/fimmu.2018.01822","volume":"9","author":"YT Tai","year":"2018","unstructured":"Tai, Y. T., Cho, S. F. & Anderson, K. C. Osteoclast immunosuppressive effects in multiple myeloma: role of programmed cell death ligand 1. Front. Immunol. 9, 1822 (2018).","journal-title":"Front. Immunol."},{"key":"39769_CR37","doi-asserted-by":"publisher","first-page":"e88053","DOI":"10.1371\/journal.pone.0088053","volume":"9","author":"E Alegre-Aguaron","year":"2014","unstructured":"Alegre-Aguaron, E. et al. Growth factor priming differentially modulates components of the extracellular matrix proteome in chondrocytes and synovium-derived stem cells. PLoS ONE 9, e88053 (2014).","journal-title":"PLoS ONE"},{"key":"39769_CR38","doi-asserted-by":"publisher","unstructured":"Werth, E. G., Rajbhandari, P., Stockwell, B. R. & Brown, L. M. Time course of changes in sorafenib-treated hepatocellular carcinoma (HCC) cells suggests involvement of phospho-regulated signaling in ferroptosis induction. Proteomics, e2000006, https:\/\/doi.org\/10.1002\/pmic.202000006 (2020).","DOI":"10.1002\/pmic.202000006"},{"key":"39769_CR39","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1158\/1535-7163.MCT-15-0798","volume":"15","author":"S Li","year":"2016","unstructured":"Li, S. et al. Elevated translation initiation factor eIF4E is an attractive therapeutic target in multiple myeloma. Mol. Cancer Ther. 15, 711\u2013719 (2016).","journal-title":"Mol. Cancer Ther."},{"key":"39769_CR40","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1182\/blood-2010-08-303073","volume":"117","author":"J Fu","year":"2011","unstructured":"Fu, J. et al. The tumor suppressor gene WWOX links the canonical and noncanonical NF-kappaB pathways in HTLV-I Tax-mediated tumorigenesis. Blood 117, 1652\u20131661 (2011).","journal-title":"Blood"},{"key":"39769_CR41","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1182\/bloodadvances.2017010348","volume":"2","author":"S Li","year":"2018","unstructured":"Li, S. et al. IMiD compounds affect CD34(+) cell fate and maturation via CRBN-induced IKZF1 degradation. Blood Adv. 2, 492\u2013504 (2018).","journal-title":"Blood Adv"},{"key":"39769_CR42","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1172\/JCI8489","volume":"105","author":"N Kurihara","year":"2000","unstructured":"Kurihara, N., Reddy, S. V., Menaa, C., Anderson, D. & Roodman, G. D. Osteoclasts expressing the measles virus nucleocapsid gene display a pagetic phenotype. J. Clin. Invest. 105, 607\u2013614 (2000).","journal-title":"J. Clin. Invest."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-023-39769-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-023-39769-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-023-39769-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,17]],"date-time":"2023-12-17T06:34:09Z","timestamp":1702794849000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-023-39769-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,17]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["39769"],"URL":"https:\/\/doi.org\/10.1038\/s41467-023-39769-8","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,17]]},"assertion":[{"value":"26 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"In the last 12 months, S.L. has received compensation as a member of Scientific Advisory Boards or Data Monitoring Committees of Janssen, Pfizer, BMS, Adaptive, GSK, Regeneron, Takeda, Sanofi, Oncopetide and Caelum Biosciences. She received research funding from Sanofi and Zentalis and owns royalties for CAEL-101. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4271"}}